Tripeptidyl-peptidase II (TPP II) inhibitory activity of ( S )-2,3-dihydro-2-(1 H -imidazol-2-yl)-1 H -indoles, a systematic SAR evaluation. Part 2
摘要:
We have systematically explored the structure-activity relationship (SAR) for a series of compounds 2 as inhibitors of tripeptidyl-peptidase II (TPP II), a serine protease responsible for the degradation of cholecystokinin-8 (CCK-8). This SAR evaluation of the core structure 2 suggest a fairly restrictive pharmacophore for such related structures, but has yielded a limited set of compounds (2b, 2c, 2d, 2s, and 2t) with potent TPP II inhibitory activity (IC50 4-11 nM). (C) 2003 Elsevier Ltd. All rights reserved.
Tripeptidyl-peptidase II (TPP II) inhibitory activity of ( S )-2,3-dihydro-2-(1 H -imidazol-2-yl)-1 H -indoles, a systematic SAR evaluation. Part 2
摘要:
We have systematically explored the structure-activity relationship (SAR) for a series of compounds 2 as inhibitors of tripeptidyl-peptidase II (TPP II), a serine protease responsible for the degradation of cholecystokinin-8 (CCK-8). This SAR evaluation of the core structure 2 suggest a fairly restrictive pharmacophore for such related structures, but has yielded a limited set of compounds (2b, 2c, 2d, 2s, and 2t) with potent TPP II inhibitory activity (IC50 4-11 nM). (C) 2003 Elsevier Ltd. All rights reserved.
The present invention is concerned with novel compounds of formula (I) which are inhibitors of a membrane tripeptidyl peptidase responsible for the inactivation of endogenous neuropeptides such as cholecystokinis (CCKs). The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.
1
wherein n is an integer 0 or 1; X represents O; S; or '(CR
4
R
5
)
m
— wherein m is an integer 1 or 2; R
4
and R
5
are each independently from each other hydrogen or C
1-4
alkyl; R
1
is C
1-6
alkylcarbonyl optionally substituted with hydroxy; C
1-6
alkyloxycarbonyl; aminoC
1-6
alkylcarbonyl wherein the C
1-6
alkyl group is optionally substituted with C
3-6
cycloalkyl; mono- and di(C
1-4
alkyl)aminoC
1-6
alkylcarbonyl; aminocarbonyl substituted with aryl; C
1-6
alkylcarbonyloxyC
1-6
alkylcarbonyl; C
1-6
alkyloxycarbonylaminoC
1-6
alkylcarbonyl wherein the amino group is optionally substituted with C
1-4
alkyl; an amino acid; C
1-6
alkyl substituted with amino; or arylcarbonyl; R
2
is an optionally substituted 5-membered heterocycle, or R
2
is optionally substituted benzimnidazole; R
3
is a bivalent radical —CH
2
CH
2
— optionally substituted with halo or phenylmethyl; or R
3
is a bivalent radical of formula
2
The present invention is concerned with novel compounds of formula (I) which are inhibitors of a membrane tripeptidyl peptidase responsible for the inactivation of endogenous neuropeptides such as cholecystokinis (CCKs). The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.
wherein n is an integer 0 or 1; X represents O; S; or —(CR
4
R
5
)
m
— wherein m is an integer 1 or 2; R
4
and R
5
are each independently from each other hydrogen or C
1-4
alkyl; R
1
is C
1-6
alkylcarbonyl optionally substituted with hydroxy; C
1-6
alkyloxycarbonyl; aminoC
1-6
alkylcarbonyl wherein the C
1-6
alkyl group is optionally substituted with C
3-6
cycloalkyl; mono- and di(C
1-4
alkyl)aminoC
1-6
alkylcarbonyl; aminocarbonyl substituted with aryl; C
1-6
alkylcarbonyloxyC
1-6
alkylcarbonyl; C
1-6
alkyloxycarbonylaminoC
1-6
alkylcarbonyl wherein the amino group is optionally substituted with C
1-4
alkyl; an amino acid; C
1-6
alkyl substituted with amino; or arylcarbonyl; R
2
is an optionally substituted 5-membered heterocycle, or R
2
is optionally substituted benzimidazole; R
3
is a bivalent radical —CH
2
CH
2
— optionally substituted with halo or phenylmethyl; or R
3
is a bivalent radical of formula